Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model (2015)

Peer-Reviewed Study · Bai RY; Staedtke V; Wanjiku T; Rudek MA; Joshi A; Gallia GL; Riggins GJ · April 10, 2015

Bai RY et al., 2015-04-10: The paper that established the polymorph difference in cancer terms: polymorph C reached the brain at effective concentrations and extended survival in a mouse glioma model, polymorph B worked but was more toxic, and polymorph A gave no benefit. It also reports which commercial tablets contained which form – Janssen and Medley mainly C, stored Teva tablets mainly A.

Based on the IR peaks of -C=O and -NH bonds, we determined that the Janssen and Medley tablets were made of mainly MBZ-C as well as the Aurochem S2017. Aurochem S2015 and Teva tablets that have been stored at RT for 2 years showed mainly the profiles of MBZ-A.

Results

Bai RY et al., 2015-04-10: The paper that established the polymorph difference in cancer terms: polymorph C reached the brain at effective concentrations and extended survival in a mouse glioma model, polymorph B worked but was more toxic, and polymorph A gave no benefit. It also reports which commercial tablets contained which form – Janssen and Medley mainly C, stored Teva tablets mainly A. Study type: preclinical pharmacokinetic and efficacy study in mice, plus IR analysis of marketed tablets. N: GL261 glioma cohorts of 5-6 mice per arm; PK cohorts of 3 mice per time point. Country: United States (Johns Hopkins), with tablets purchased in Brazil (2013) and the United States (2011). Dose: 50 mg/kg/day oral gavage for the first 20 days then 5 days a week; single-dose PK at 50 mg/kg; elacridar 50 mg/kg. Funder: 'Accelerate Brain Cancer Cure foundation to GJR, the Virginia and D.K. Ludwig Fund for Cancer Research, generous support from Peter Jennison, the Irving J Sherman Research Professorship in Neurosurgery to GJR and National Institute of Neurological Disorders and Stroke (R25NS065729) to VS, NIH P30-CA006973, UL1-RR025005 and 1S10RR026824-01 to MAR.' Conflicts: 'BRY, VS, AJ and GJR are the inventors of a provisional patent application titled Mebendazole Polymorph for Brain Tumors' (see MBA-06). Products: Janssen (Pantelmin, Brazil), Medley (Brazil), Teva (US, discontinued Oct 2011), Aurochem (India) S2015/S2017. Comparator: vehicle control, and elacridar alone. Quoted passage is prose from the Results section. Also filed as MBB-36 (claims C5, C8). Study type: animal.